Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Expands Pediatric Use of Entrectinib, Approves Pellet Form
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive CNS tumors in pediatric patients.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2023
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA OKs FoundationOne Liquid CDx as Companion Test for Entrectinib
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 05, 2023
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
CDSCO Tells Roche India to Submit Phase IV Trial Protocol for Entrectinib
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 02, 2023
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Roche India Gets CDSCO Nod to Market Entrectinib Capsules
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2022
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Chugai Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Thermo Fisher Signs CDx Agreement with Chugai Pharma
Details : Approval by the MHLW would accelerate access to Chugai's targeted therapy via a locally administered, next-generation sequencing (NGS) biomarker test.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
August 07, 2020
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Chugai Pharmaceutical
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
NICE Recommends Rozlytrek for Treating NSCLC in the UK
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 16, 2020
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Health Canada OKs Rozlytrek for NTRK+ Advanced or Metastatic Tumors
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive brain metatases.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 28, 2020
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Chugai's Rozlytrek Approved for ROS1+ NSCLC in Japan
Details : Rozlytrek (entrectinib) is a kinase inhibitor indicated for the treatment of adult patients with ROS1-positive metastatic non-small cell lung cancer as detected by an FDA-approved test.
Product Name : Rozlytrek
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 21, 2020
Lead Product(s) : Entrectinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable